33,890 papers found
Refreshing results…
A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study
Tendon Repair and Regeneration Using Bioinspired Fibrillation Engineering That Mimicked the Structure and Mechanics of Natural Tissue
The modulation of expectation violation on attention: Evidence from the spatial cueing effects
Rgl-exomiR-7972, a novel plant exosomal microRNA derived from fresh Rehmanniae Radix, ameliorated lipopolysaccharide-induced acute lung injury and gut dysbiosis
Moving beyond Likert and Traditional Forced-Choice Scales: A Comprehensive Investigation of the Graded Forced-Choice Format
Physical Activity and High-Sensitivity C-Reactive Protein in Pregnancy: Does It Matter during Leisure or Work?
Stretchable, skin‐conformable neuromorphic system for tactile sensory recognizing and encoding
The anoikis-related gene signature predicts survival accurately in colon adenocarcinoma
Intensification of Mesoscale Convective Systems in the East Asian Rainband Over the Past Two Decades
Value of proteinuria in evaluating the severity of HELLP and its maternal and neonatal outcomes
Thin, soft, wearable system for continuous wireless monitoring of artery blood pressure
Supplementary Figure 1 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
Supplementary Figure 2 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
Supplementary Methods from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
Supplementary Table 2 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
Supplementary Table 1 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
Data from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814
Methionine restriction-induced sulfur deficiency impairs antitumour immunity partially through gut microbiota
Food flavor analysis 4.0: A cross-domain application of machine learning
Missing publications? Read more about our data sources.